The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

TNX-1700, a fusion protein of TFF2 and albumin, is in preclinical development for the treatment of gastric and colorectal cancer in combination with PD-1 blockade. TNX-1700, in-licensed from Columbia ...

The 2026 Design and Verification Conference and Exhibition U.S. (DVCon U.S.), sponsored by Accellera Systems Initiative (Accellera), concluded earlier this month with record attendance at its new ...

A poster presentation often discusses research or an academic project using a poster that can be read and viewed by a large audience. The individual presenter(s) will use their posters to illustrate ...

BERKELEY HEIGHTS, N.J., March 17, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, today ...

The presentations will be made available in the Publications section of the Bicycle Therapeutics website at the beginning of the poster session. Bicycle Therapeutics is headquartered in Cambridge, UK, ...

The Capstone Poster Presentation highlights how final-year engineering students apply their knowledge to real-world challenges. Faculty, industry professionals and the Concordia community are invited ...

Copies of the Company’s presentations will be available under the Scientific Presentations tab on the Tonix website at www.tonixpharma.com. About TNX-1700 TNX-1700, a fusion protein of TFF2 and ...

WALTHAM, Mass., March 20, 2026 (GLOBE NEWSWIRE)-- Sironax, a global clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunological, ...

The Capstone Poster Presentation highlights how final-year engineering students apply their knowledge to real-world challenges. Faculty, industry professionals and the Concordia community are invited ...

KING OF PRUSSIA, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”) , a clinical-stage biotechnology company specializing in molecular glue degraders, today announced that it ...